JP7030690B2 - 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤 - Google Patents

核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤 Download PDF

Info

Publication number
JP7030690B2
JP7030690B2 JP2018521205A JP2018521205A JP7030690B2 JP 7030690 B2 JP7030690 B2 JP 7030690B2 JP 2018521205 A JP2018521205 A JP 2018521205A JP 2018521205 A JP2018521205 A JP 2018521205A JP 7030690 B2 JP7030690 B2 JP 7030690B2
Authority
JP
Japan
Prior art keywords
compound
compound according
composition
lipid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018521205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533573A5 (cg-RX-API-DMAC7.html
JP2018533573A (ja
Inventor
スティーブン・エム・アンセル
シンヤオ・ドゥ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acuitas Therapeutics Inc
Original Assignee
Acuitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acuitas Therapeutics Inc filed Critical Acuitas Therapeutics Inc
Publication of JP2018533573A publication Critical patent/JP2018533573A/ja
Publication of JP2018533573A5 publication Critical patent/JP2018533573A5/ja
Priority to JP2022025427A priority Critical patent/JP7453269B2/ja
Application granted granted Critical
Publication of JP7030690B2 publication Critical patent/JP7030690B2/ja
Priority to JP2024034511A priority patent/JP7789819B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2018521205A 2015-10-28 2016-10-28 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤 Active JP7030690B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022025427A JP7453269B2 (ja) 2015-10-28 2022-02-22 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤
JP2024034511A JP7789819B2 (ja) 2015-10-28 2024-03-07 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562247616P 2015-10-28 2015-10-28
US62/247,616 2015-10-28
US201662328244P 2016-04-27 2016-04-27
US62/328,244 2016-04-27
PCT/US2016/059575 WO2017075531A1 (en) 2015-10-28 2016-10-28 Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022025427A Division JP7453269B2 (ja) 2015-10-28 2022-02-22 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤

Publications (3)

Publication Number Publication Date
JP2018533573A JP2018533573A (ja) 2018-11-15
JP2018533573A5 JP2018533573A5 (cg-RX-API-DMAC7.html) 2019-12-05
JP7030690B2 true JP7030690B2 (ja) 2022-03-07

Family

ID=57256479

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018521205A Active JP7030690B2 (ja) 2015-10-28 2016-10-28 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤
JP2022025427A Active JP7453269B2 (ja) 2015-10-28 2022-02-22 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤
JP2024034511A Active JP7789819B2 (ja) 2015-10-28 2024-03-07 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022025427A Active JP7453269B2 (ja) 2015-10-28 2022-02-22 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤
JP2024034511A Active JP7789819B2 (ja) 2015-10-28 2024-03-07 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤

Country Status (19)

Country Link
US (5) US10166298B2 (cg-RX-API-DMAC7.html)
EP (2) EP3368507B1 (cg-RX-API-DMAC7.html)
JP (3) JP7030690B2 (cg-RX-API-DMAC7.html)
CN (2) CN113636947A (cg-RX-API-DMAC7.html)
AU (3) AU2016343803B2 (cg-RX-API-DMAC7.html)
CA (2) CA3201644A1 (cg-RX-API-DMAC7.html)
DK (1) DK3368507T3 (cg-RX-API-DMAC7.html)
ES (1) ES2938557T3 (cg-RX-API-DMAC7.html)
FI (1) FI3368507T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230209T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061564T2 (cg-RX-API-DMAC7.html)
IL (3) IL307179A (cg-RX-API-DMAC7.html)
LT (1) LT3368507T (cg-RX-API-DMAC7.html)
PL (1) PL3368507T3 (cg-RX-API-DMAC7.html)
PT (1) PT3368507T (cg-RX-API-DMAC7.html)
RS (1) RS63986B1 (cg-RX-API-DMAC7.html)
SI (1) SI3368507T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300052T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017075531A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024081666A (ja) * 2015-10-28 2024-06-18 アクイタス セラピューティクス インコーポレイテッド 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤

Families Citing this family (634)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
HRP20160805T1 (hr) 2010-07-06 2016-08-12 Glaxosmithkline Biologicals Sa Imuniziranje velikih sisavaca malim dozama rna
CA2804396C (en) 2010-07-06 2021-06-29 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
SI3981427T1 (sl) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
CN103269713B (zh) 2010-10-11 2016-01-20 诺华有限公司 抗原递送平台
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
CA3198966A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Cleavable lipids
EP2717893B1 (en) 2011-06-08 2019-05-08 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
ES3009962T3 (en) 2014-04-23 2025-03-31 Modernatx Inc Nucleic acid vaccines
CN106795096B (zh) 2014-06-25 2020-05-29 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
EP3283059B1 (en) 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Method for producing rna compositions
EP3289083A4 (en) * 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
HRP20240865T1 (hr) 2015-06-29 2024-10-11 Acuitas Therapeutics Inc. Lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
EP3331557B1 (en) 2015-08-04 2021-04-07 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
AU2016366978B2 (en) * 2015-12-10 2022-07-28 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
JP7065036B2 (ja) 2015-12-17 2022-05-11 モダーナティエックス・インコーポレイテッド メチルマロニルＣｏＡムターゼをコードするポリヌクレオチド
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
SMT202200252T1 (it) 2015-12-22 2022-07-21 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti
MA45050A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie
US12128113B2 (en) * 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
MA45053A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique
KR102533456B1 (ko) 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
JP2019519601A (ja) * 2016-05-18 2019-07-11 モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ． 急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド
WO2017201317A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
MA45036A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
WO2018057847A1 (en) 2016-09-23 2018-03-29 Duke University Unstructured non-repetitive polypeptides having lcst behavior
EP3528852B1 (en) 2016-10-20 2025-09-03 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
RU2765874C2 (ru) 2016-10-26 2022-02-04 МОДЕРНАТиЭкс, ИНК. Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения
EP3532103B1 (en) 2016-10-26 2025-12-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
MX2019004913A (es) * 2016-10-26 2019-09-16 Curevac Ag Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
US20190274968A1 (en) * 2016-10-27 2019-09-12 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
ES2928358T3 (es) 2016-11-08 2022-11-17 Univ Ramot Lípidos catiónicos para el suministro de ácidos nucleicos y preparación de los mismos
CN110167587A (zh) 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
EP3558354A1 (en) 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
BR112019014314A2 (pt) 2017-01-11 2020-02-18 The Trustees Of The University Of Pennsylvania Composição, e, método de indução de uma resposta imune adaptativa contra vírus zika.
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
EP3609534A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. WIDE SPECTRUM INFLUENZA VIRUS VACCINE
SI3596041T1 (sl) 2017-03-15 2023-02-28 Modernatx, Inc. Spojina in sestavki za intracelično dostavljanje terapevtskih sredstev
CA3056133A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
EP3596112A2 (en) 2017-03-17 2020-01-22 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
JP2020513824A (ja) 2017-03-24 2020-05-21 キュアバック アーゲー Ｃｒｉｓｐｒ関連タンパク質をコードする核酸、及びその使用
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018191719A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
JP7464954B2 (ja) 2017-04-27 2024-04-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃ型肝炎ウイルスに対するヌクレオシド修飾ｍＲＮＡ－脂質ナノ粒子系統ワクチン
EP4410317A3 (en) 2017-04-28 2024-10-30 Acuitas Therapeutics Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
WO2018225871A1 (ja) * 2017-06-09 2018-12-13 協和発酵キリン株式会社 カチオン性脂質としての化合物
WO2018231990A2 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP3641834B1 (en) 2017-06-19 2023-10-04 Translate Bio, Inc. Messenger rna therapy for the treatment of friedreich's ataxia
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
WO2019036008A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP3668834B1 (en) * 2017-08-17 2024-10-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
MA51306A (fr) 2017-12-20 2020-10-28 Translate Bio Inc Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
MX2020006843A (es) 2017-12-27 2020-09-03 Takeda Pharmaceuticals Co Nanoparticula de lipido que contiene acido nucleico y uso de la misma.
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
WO2019152557A1 (en) 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
EP4227319B1 (en) 2018-04-17 2025-11-26 CureVac SE Novel rsv rna molecules and compositions for vaccination
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
WO2019222277A1 (en) 2018-05-15 2019-11-21 Translate Bio, Inc. Subcutaneous delivery of messenger rna
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
US12076439B2 (en) 2018-05-24 2024-09-03 Translate Bio, Inc. Thioester cationic lipids
AU2019277361B2 (en) 2018-05-30 2025-04-24 Translate Bio, Inc. Messenger RNA vaccines and uses thereof
CN112424214A (zh) 2018-05-30 2021-02-26 川斯勒佰尔公司 包含甾族部分的阳离子脂质
JP2021525743A (ja) 2018-05-30 2021-09-27 トランスレイト バイオ， インコーポレイテッド リン酸エステルカチオン性脂質
MA52766A (fr) 2018-05-30 2021-04-14 Translate Bio Inc Lipides cationiques vitaminiques
EP3807413B1 (en) 2018-06-18 2025-05-21 Research Institute at Nationwide Children's Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
EP3813874A1 (en) 2018-06-27 2021-05-05 CureVac AG Novel lassa virus rna molecules and compositions for vaccination
EP3826608A1 (en) 2018-07-23 2021-06-02 Translate Bio, Inc. Dry power formulations for messenger rna
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
US11357726B2 (en) 2018-08-29 2022-06-14 Translate Bio, Inc. Process of preparing mRNA-loaded lipid nanoparticles
AU2019338535A1 (en) 2018-09-14 2021-04-15 Modernatx, Inc. Methods and compositions for treating cancer using mRNA therapeutics
EP3849617A1 (en) 2018-09-14 2021-07-21 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
AU2019345067A1 (en) * 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
IL322436A (en) 2018-09-21 2025-09-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
CA3113151A1 (en) 2018-10-01 2020-04-09 Johannes Gutenberg-Universitat Mainz Rna particles comprising polysarcosine
US20220009878A1 (en) * 2018-10-02 2022-01-13 Intellia Therapeutics, Inc. Ionizable amine lipids
EP3867225A1 (en) * 2018-10-18 2021-08-25 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
US20210381006A1 (en) 2018-10-18 2021-12-09 Takeda Pharmaceutical Company Limited Method for activation/proliferation of t cells
WO2020081933A1 (en) 2018-10-19 2020-04-23 Translate Bio, Inc. Pumpless encapsulation of messenger rna
WO2020097376A1 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Multi-peg lipid compounds
EP3876914A2 (en) 2018-11-09 2021-09-15 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
EP3876994A2 (en) 2018-11-09 2021-09-15 Translate Bio, Inc. Peg lipidoid compounds
BR112021008974A2 (pt) 2018-11-09 2021-08-03 Translate Bio, Inc. lipídios de 2,5-dioxopiperazina com frações éster, tioéster, dissulfeto e anidrido intercaladas
US20220096612A1 (en) 2018-11-12 2022-03-31 Translatebioinc Methods for inducing immune tolerance
AU2019383413A1 (en) 2018-11-21 2021-05-27 Translate Bio, Inc. Cationic lipid compounds and compositions thereof for use in the delivery of messenger RNA
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
AU2019410737A1 (en) 2018-12-21 2021-06-10 CureVac SE RNA for malaria vaccines
AU2020206109B2 (en) 2019-01-07 2024-12-19 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CA3125511A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
US20220177423A1 (en) 2019-04-18 2022-06-09 Translate Bio, Inc. Cystine cationic lipids
ES2972014T3 (es) 2019-04-22 2024-06-10 Translate Bio Inc Lípidos catiónicos de tioéster
WO2020227085A1 (en) 2019-05-03 2020-11-12 Translate Bio, Inc. Di-thioester cationic lipids
AU2020268388A1 (en) 2019-05-07 2021-12-02 Modernatx, Inc. Polynucleotides for disrupting immune cell activity and methods of use thereof
WO2020227537A1 (en) 2019-05-07 2020-11-12 Modernatx, Inc Differentially expressed immune cell micrornas for regulation of protein expression
CA3139032A1 (en) 2019-05-22 2020-11-26 Robert Alexander WESSELHOEFT Circular rna compositions and methods
US20220226244A1 (en) 2019-05-31 2022-07-21 Translate Bio, Inc. Macrocyclic lipids
JP7744011B2 (ja) 2019-06-07 2025-09-25 スクライブ・セラピューティクス・インコーポレイテッド 操作されたｃａｓｘシステム
MA56520A (fr) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Co Construction de l'interleukine 12 recombinante et ses utilisations
EP3986452A1 (en) 2019-06-18 2022-04-27 CureVac AG Rotavirus mrna vaccine
WO2020255007A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
WO2020255011A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
WO2020255010A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
CN114206379A (zh) 2019-06-18 2022-03-18 爱尔兰詹森科学公司 乙型肝炎病毒(hbv)疫苗和抗pd-1抗体的组合
WO2020255062A1 (en) 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
WO2020257611A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
JP7724161B2 (ja) 2019-06-21 2025-08-15 トランスレイト バイオ， インコーポレイテッド トリシンおよびクエン酸脂質
KR20220078557A (ko) 2019-07-08 2022-06-10 트랜슬레이트 바이오 인코포레이티드 개선된 mrna 로딩된 지질 나노입자 및 이의 제조 방법
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP3999642A1 (en) 2019-07-19 2022-05-25 Flagship Pioneering Innovations VI, LLC Recombinase compositions and methods of use
US12144871B2 (en) 2019-07-23 2024-11-19 Translate Bio, Inc. Stable compositions of MRNA-loaded lipid nanoparticles and processes of making
JP7769325B2 (ja) * 2019-07-23 2025-11-13 株式会社東芝 Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット
US20220280639A1 (en) 2019-07-31 2022-09-08 Modernatx, Inc. Compositions and methods for delivery of rna interference agents to immune cells
WO2021026358A1 (en) 2019-08-07 2021-02-11 Moderna TX, Inc. Compositions and methods for enhanced delivery of agents
CA3144902A1 (en) 2019-08-14 2022-01-19 Andreas Thess Rna combinations and compositions with decreased immunostimulatory properties
HRP20241255T1 (hr) 2019-08-14 2024-12-06 Acuitas Therapeutics, Inc. Poboljšane lipidne nanočestice za isporuku nukleinskih kiselina
CN114929205B (zh) 2019-09-06 2024-09-03 世代生物公司 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
CN120423969A (zh) 2019-09-19 2025-08-05 摩登纳特斯有限公司 用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物
US20220411361A1 (en) * 2019-09-19 2022-12-29 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
MX2022003394A (es) 2019-09-20 2022-06-22 Translate Bio Inc Arnm que codifica cftr manipulado.
AU2020355000A1 (en) 2019-09-23 2022-03-17 Omega Therapeutics, Inc. Compositions and methods for modulating apolipoprotein B (APOB) gene expression
JP2022548399A (ja) 2019-09-23 2022-11-18 オメガ セラピューティクス， インコーポレイテッド 肝細胞核因子４－アルファ（ＨＮＦ４α）遺伝子発現をモジュレートするための組成物および方法
WO2021076805A1 (en) 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
US20210145860A1 (en) 2019-10-21 2021-05-20 Translate Bio, Inc. Compositions, methods and uses of messenger rna
WO2021102411A1 (en) 2019-11-22 2021-05-27 Generation Bio Co. Ionizable lipids and nanoparticle compositions thereof
EP4289951A3 (en) 2019-12-04 2024-03-13 Orna Therapeutics, Inc. Circular rna compositions and methods
US20230051811A1 (en) 2019-12-20 2023-02-16 Translate Bio, Inc Rectal delivery of messenger rna
US12053551B2 (en) 2019-12-20 2024-08-06 Translate Bio, Inc. Process of preparing mRNA-loaded lipid nanoparticles
CA3163161A1 (en) 2020-01-09 2021-07-15 Gregory Lawrence HAMILTON Nanomaterials
JP2023510308A (ja) 2020-01-10 2023-03-13 モデルナティエックス インコーポレイテッド 寛容原性樹状細胞を作る方法
WO2021142245A1 (en) 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
US20230130155A1 (en) 2020-01-30 2023-04-27 Modernatx, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
CA3160511A1 (en) 2020-02-04 2021-08-12 Susanne RAUCH Coronavirus vaccine
JP7744354B2 (ja) 2020-02-25 2025-09-25 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａ担持脂質ナノ粒子を調製する改善された方法
EP4118164A1 (en) 2020-03-11 2023-01-18 AdvanSix Resins & Chemicals LLC Surfactants for oil and gas production
EP4117624A1 (en) * 2020-03-11 2023-01-18 AdvanSix Resins & Chemicals LLC Surfactants for healthcare products
JP2023517326A (ja) 2020-03-11 2023-04-25 オメガ セラピューティクス， インコーポレイテッド フォークヘッドボックスｐ３（ｆｏｘｐ３）遺伝子発現をモジュレートするための組成物および方法
US20240245805A1 (en) 2020-03-20 2024-07-25 Orna Therapeutics, Inc. Circular rna compositions and methods
MX2022011805A (es) 2020-03-24 2023-01-11 Generation Bio Co Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
CN115667531A (zh) 2020-03-24 2023-01-31 世代生物公司 非病毒DNA载体和其用于表达戈谢（Gaucher）治疗剂的用途
JP7746280B2 (ja) 2020-03-27 2025-09-30 ジェネレーション バイオ カンパニー 新規脂質及びそれらのナノ粒子組成物
WO2021198157A1 (en) 2020-03-30 2021-10-07 BioNTech SE Rna compositions targeting claudin-18.2
WO2021207710A2 (en) 2020-04-09 2021-10-14 Verve Therapeutics, Inc. Base editing of angptl3 and methods of using same for treatment of disease
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
US12023376B1 (en) 2020-04-17 2024-07-02 Triad National Security, Llc Conserved region T cell vaccines for coronavirus and methods of use
WO2021213924A1 (en) 2020-04-22 2021-10-28 BioNTech SE Coronavirus vaccine
US20230190954A1 (en) 2020-05-07 2023-06-22 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
EP4146342A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Improved compositions for cftr mrna therapy
AU2021269042A1 (en) 2020-05-07 2023-02-02 Translate Bio, Inc. Optimized nucleotide sequences encoding SARS-CoV-2 antigens
US20230226219A1 (en) 2020-05-14 2023-07-20 Translate Bio, Inc. Peg lipidoid compounds
CA3183399A1 (en) 2020-05-15 2021-11-18 Translate Bio, Inc. Lipid nanoparticle formulations for mrna delivery
JP2023527309A (ja) 2020-05-19 2023-06-28 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
IL298363A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
CN116322760A (zh) 2020-05-20 2023-06-23 旗舰创业创新第六有限责任公司 冠状病毒抗原组合物及其用途
CA3170740A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
EP4158032A2 (en) 2020-05-29 2023-04-05 Flagship Pioneering Innovations VI, LLC Trem compositions and methods relating thereto
IL298539A (en) 2020-05-29 2023-01-01 Flagship Pioneering Innovations Vi Llc Trem compositions and methods relating thereto
MX2022016332A (es) 2020-06-15 2023-04-03 Res Inst Nationwide Childrens Hospital Administracion de vectores de virus adenoasociados para distrofias musculares.
WO2025056938A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
US20240307556A1 (en) 2020-07-02 2024-09-19 Maritime Therapeutics, Inc. Compositions and methods for reverse gene therapy
WO2022008613A1 (en) 2020-07-08 2022-01-13 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
FI4182297T3 (fi) 2020-07-16 2025-12-05 Acuitas Therapeutics Inc Kationisia lipidejä käytettäväksi lipidinanohiukkasissa
BR112023001648A2 (pt) 2020-07-27 2023-04-04 Anjarium Biosciences Ag Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
CA3189854A1 (en) 2020-08-06 2022-02-10 Modernatx, Inc. Compositions for the delivery of payload molecules to airway epithelium
CN114073677B (zh) * 2020-08-20 2023-06-09 深圳深信生物科技有限公司 一种脂质纳米颗粒
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
EP4157344A2 (en) 2020-08-31 2023-04-05 CureVac SE Multivalent nucleic acid based coronavirus vaccines
IL300947A (en) 2020-09-03 2023-04-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
KR20230083323A (ko) 2020-10-06 2023-06-09 트랜슬레이트 바이오 인코포레이티드 개선된 지질 나노입자 공정 및 제형화
IL301973A (en) 2020-10-12 2023-06-01 Translate Bio Inc Improved process of preparing mrna-loaded lipid nanoparticles
WO2022081548A1 (en) 2020-10-12 2022-04-21 Translate Bio, Inc. Improved process of preparing ice-based lipid nanoparticles
MX2023004371A (es) * 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
US20220160633A1 (en) 2020-11-09 2022-05-26 Translate Bio, Inc. Compositions for delivery of codon-optimized mrna
US20240041785A1 (en) 2020-11-16 2024-02-08 BioNTech SE Compositions and methods for stabilization of lipid nanoparticle mrna vaccines
AR124065A1 (es) * 2020-11-16 2023-02-08 BioNTech SE Composiciones de lnp que comprenden rna y métodos para preparar, almacenar y utilizar las mismas
JP2023552681A (ja) * 2020-11-16 2023-12-19 ビオンテック・ソシエタス・エウロパエア 製剤安定化の向上および凍結乾燥プロセスの改善
WO2022218503A1 (en) * 2021-04-12 2022-10-20 BioNTech SE Lnp compositions comprising rna and methods for preparing, storing and using the same
AU2021377746A1 (en) * 2020-11-16 2023-06-08 BioNTech SE Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same
TW202237148A (zh) * 2020-11-16 2022-10-01 德商拜恩迪克公司 包含rna之lnp組合物以及製備、儲存及使用彼之方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
KR20230113580A (ko) 2020-11-25 2023-07-31 트랜슬레이트 바이오 인코포레이티드 안정한 액체 지질 나노입자 제형
WO2022112855A1 (en) * 2020-11-27 2022-06-02 Guangzhou Ribobio Co., Ltd Lipid compound and the composition thereof
CN113185421B (zh) * 2020-11-27 2022-01-25 广州市锐博生物科技有限公司 脂质化合物及其组合物
US20230242474A1 (en) * 2020-11-27 2023-08-03 Guangzhou Ribobio Co., Ltd Lipid compound and the composition thereof
GB2616584A (en) 2020-12-03 2023-09-13 Scribe Therapeutics Inc Engineered class 2 type V CRISPR systems
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
CA3205569A1 (en) 2020-12-22 2022-06-30 CureVac SE Rna vaccine against sars-cov-2 variants
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
US20240175020A1 (en) 2020-12-23 2024-05-30 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
EP4267740A1 (en) 2020-12-28 2023-11-01 Arcturus Therapeutics, Inc. Transcription activator-like effector nucleases (talens) targeting hbv
CN116323627B (zh) * 2021-01-14 2025-10-17 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
EP4277929A1 (en) 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies
WO2022152109A2 (en) * 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CA3208267A1 (en) * 2021-01-15 2022-07-21 Pfizer Inc. Methods for producing of lipids
JP2024505449A (ja) 2021-01-20 2024-02-06 ビーム セラピューティクス インク． 生分解性特徴を含むナノ材料
US20240102065A1 (en) 2021-01-27 2024-03-28 CureVac SE Method of reducing the immunostimulatory properties of in vitro transcribed rna
CN112961091B (zh) * 2021-02-07 2022-06-17 深圳深信生物科技有限公司 一种氨基脂质化合物及其制备方法和用途
US20240124396A1 (en) * 2021-02-07 2024-04-18 Shenzhen Shenxin Biotechnology Co., Ltd. Amino lipid compound, preparation method therefor, and use thereof
KR20230145124A (ko) 2021-02-08 2023-10-17 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 불포화된 덴드리머 조성물, 관련된 제형, 및 이의 사용 방법
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2022204219A1 (en) 2021-03-22 2022-09-29 Recode Therapeutics, Inc. Compositions and methods for targeted delivery to cells
MX2023011243A (es) 2021-03-23 2023-12-14 Recode Therapeutics Inc Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos.
US20250268994A1 (en) 2021-03-25 2025-08-28 Translate Bio, Inc. Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof
KR20230159887A (ko) 2021-03-25 2023-11-22 쇼오트 파르마 아게 운트 코. 카게아아 약학적 용기
JP2024511206A (ja) 2021-03-26 2024-03-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
AU2022249357A1 (en) 2021-04-01 2023-10-12 Modernatx, Inc. Methods for identification and ratio determination of rna species in multivalent rna compositions
WO2022214026A1 (zh) * 2021-04-08 2022-10-13 厦门赛诺邦格生物科技股份有限公司 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
WO2022215036A1 (en) 2021-04-08 2022-10-13 Vaxthera Sas Coronavirus vaccine comprising a mosaic protein
CN115197079A (zh) * 2021-04-08 2022-10-18 厦门赛诺邦格生物科技股份有限公司 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
CA3216060A1 (en) * 2021-04-09 2022-10-13 Pfizer Inc. Methods for producing of lipids
WO2022218891A2 (en) 2021-04-12 2022-10-20 BioNTech SE Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
IL307526A (en) * 2021-04-13 2023-12-01 Westgene Biopharma Co Ltd Ionizable lipids and preparations for the transport of nucleic acids
US20250073351A1 (en) 2021-04-19 2025-03-06 Translate Bio, Inc. Improved compositions for delivery of mrna
JP2024517427A (ja) 2021-04-20 2024-04-22 アンジャリウム バイオサイエンシズ エージー アミロ－α－１，６－グルコシダーゼ、４－α－グルカノトランスフェラーゼをコードするＤＮＡ分子の組成物、その作製の方法、及びその使用の方法
CA3216585A1 (en) 2021-04-27 2022-11-03 Nathaniel SILVER Non-viral dna vectors expressing therapeutic antibodies and uses thereof
US20240216535A1 (en) 2021-04-27 2024-07-04 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2022233880A1 (en) 2021-05-03 2022-11-10 Curevac Ag Improved nucleic acid sequence for cell type specific expression
WO2022235853A1 (en) 2021-05-04 2022-11-10 BioNTech SE Immunogen selection
JP7664392B2 (ja) 2021-05-24 2025-04-17 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質化合物及び脂質ナノ粒子組成物
WO2022251665A1 (en) * 2021-05-28 2022-12-01 Renagade Therapeutics Management Inc. Lipid nanoparticles and methods of use thereof
WO2022261490A2 (en) 2021-06-10 2022-12-15 Orna Therapeutics, Inc. Circular rna compositions and methods
AU2022291742A1 (en) 2021-06-14 2023-12-21 Generation Bio Co. Cationic lipids and compositions thereof
WO2022269041A1 (en) 2021-06-24 2022-12-29 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Continuous flow process for production of cationic lipids
EP4183770A1 (en) 2021-11-22 2023-05-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Continuous flow process for production of cationic lipids
JP2024527541A (ja) 2021-07-01 2024-07-25 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａの送達のための組成物
EP4367242A2 (en) 2021-07-07 2024-05-15 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
US20250009780A1 (en) 2021-07-15 2025-01-09 BioNTech SE Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers
CN113264842B (zh) * 2021-07-21 2022-03-01 苏州科锐迈德生物医药科技有限公司 一种脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂
EP4377457A1 (en) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Trem compositions and uses thereof
KR20240042414A (ko) 2021-07-29 2024-04-02 비온테크 에스이 흑색종의 치료용 조성물 및 방법
US20240342206A1 (en) 2021-07-30 2024-10-17 CureVac SE mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
US20240401006A1 (en) 2021-08-04 2024-12-05 Moderna TX, Inc. Mrnas encoding chimeric metabolic reprogramming polypeptides and uses thereof
WO2023015200A1 (en) * 2021-08-04 2023-02-09 The Trustees Of The University Of Pennsylvania Amniotic fluid stabilized compositions and methods for in utero delivery of therapeutic agents
CN115703714B (zh) * 2021-08-13 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
CN115703713B (zh) * 2021-08-13 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
CN115710192B (zh) * 2021-08-23 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
CN115710193B (zh) * 2021-08-23 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
CN115710191B (zh) * 2021-08-23 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
EP4141013A1 (en) 2021-08-31 2023-03-01 Studiengesellschaft Kohle mbH Stereochemically pure lipids for nucleic acid delivery
WO2023030635A1 (en) 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
CN115745819B (zh) * 2021-09-03 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
AU2022336664A1 (en) 2021-09-03 2024-01-18 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
CA3229889A1 (en) 2021-09-03 2023-03-09 Glaxosmithkline Biologicals Sa Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
TW202325263A (zh) 2021-09-14 2023-07-01 美商雷納嘉德醫療管理公司 非環狀脂質及其使用方法
JP2024533865A (ja) 2021-09-14 2024-09-12 レナゲード セラピューティクス マネージメント インコーポレイテッド 環状脂質及びその使用方法
JP2024534428A (ja) 2021-09-17 2024-09-20 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 環状ポリリボヌクレオチドを生成するための組成物及び方法
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
WO2023056033A1 (en) 2021-09-30 2023-04-06 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
AR127312A1 (es) * 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
AU2022361755A1 (en) 2021-10-08 2024-04-04 Pfizer Inc. Immunogenic lnp compositions and methods thereof
WO2023064469A1 (en) 2021-10-13 2023-04-20 Modernatx, Inc. Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
TW202327646A (zh) 2021-10-15 2023-07-16 美商輝瑞大藥廠 Rna分子
MX2024004618A (es) 2021-10-18 2024-07-12 Flagship Pioneering Innovations Vi Llc Composiciones y metodos para purificar polirribonucleotidos.
US20250295755A1 (en) 2021-10-22 2025-09-25 Sail Biomedicines, Inc. Mrna vaccine composition
CA3234578A1 (en) 2021-10-22 2023-04-27 Advait Vijay Badkar Compositions for administration of different doses of rna
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023077170A1 (en) 2021-11-01 2023-05-04 Modernatx, Inc. Polynucleotides encoding integrin beta-6 and methods of use thereof
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
WO2023083434A1 (en) 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
AU2022388747A1 (en) 2021-11-10 2024-06-20 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
CN118829423A (zh) 2021-11-12 2024-10-22 摩登纳特斯有限公司 用于将有效载荷分子递送至气道上皮的组合物
CN118829625A (zh) 2021-11-16 2024-10-22 赛欧生物医药股份有限公司 新型可电离脂质和脂质纳米颗粒以及它们的使用方法
JP2024542260A (ja) 2021-11-22 2024-11-13 セイル バイオメディシンズ インコーポレイテッド 新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
CN118488834A (zh) 2021-11-23 2024-08-13 赛欧生物医药股份有限公司 细菌源性脂质组合物和其用途
KR20240125931A (ko) 2021-11-24 2024-08-20 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 수두-대상포진 바이러스 면역원 조성물 및 이의 용도
US20250352638A1 (en) 2021-11-24 2025-11-20 Flagship Pioneering Innovations Vi, Llc Coronavirus immunogen compositions and their uses
MX2024006440A (es) 2021-11-24 2024-08-19 Flagship Pioneering Innovations Vi Llc Composiciones inmunogenicas y sus usos.
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
AR127892A1 (es) * 2021-12-10 2024-03-06 Modernatx Inc Compuestos y composiciones para la administración de agentes terapéuticos
US12129223B2 (en) 2021-12-16 2024-10-29 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
TW202340460A (zh) 2021-12-17 2023-10-16 美商旗艦先鋒創新有限責任公司 用於在變性條件下富集環狀ｒｎａ之方法
PE20241621A1 (es) 2021-12-17 2024-08-07 Pfizer Composiciones de polinucleotidos y sus usos
EP4452239A1 (en) 2021-12-20 2024-10-30 Sail Biomedicines, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
KR20240117149A (ko) 2021-12-22 2024-07-31 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
US20230201817A1 (en) 2021-12-23 2023-06-29 Biontech Delivery Technologies Gmbh Modular drug production system
EP4452337A1 (en) 2021-12-23 2024-10-30 Flagship Pioneering Innovations VI, LLC Circular polyribonucleotides encoding antifusogenic polypeptides
CA3243054A1 (en) * 2021-12-23 2025-04-08 Renagade Therapeutics Management Inc. Constrained Lipids and Associated Utilization Processes
CA3241492A1 (en) * 2021-12-23 2023-06-29 Suzhou Abogen Biosciences Co., Ltd. Lipid compound and lipid nanoparticle composition
CN114249662B (zh) * 2021-12-27 2024-06-21 硅羿科技（上海）有限公司 一种药用脂质体辅料alc-0315的制备方法
WO2023126053A1 (en) 2021-12-28 2023-07-06 BioNTech SE Lipid-based formulations for administration of rna
CA3242974A1 (en) * 2021-12-29 2023-07-06 Shanghai Senhui Medicine Co., Ltd. LIPID AND COMPOSITION USED FOR ADMINISTRATION
CN114044741B (zh) * 2022-01-13 2022-04-15 北京悦康科创医药科技股份有限公司 一种阳离子脂质化合物、包含其的组合物及用途
EP4463475A2 (en) 2022-01-14 2024-11-20 Anjarium Biosciences AG Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
EP4466029A1 (en) 2022-01-21 2024-11-27 Orna Therapeutics, Inc. Systemic administration of circular rna polynucleotides encoding muscle proteins or protein complexes
WO2023144193A1 (en) 2022-01-25 2023-08-03 CureVac SE Mrnas for treatment of hereditary tyrosinemia type i
CN114409554A (zh) * 2022-01-27 2022-04-29 英维沃生物科技(苏州)有限公司 一种新型阳离子脂质化合物及其组合物和用途
EP4469063A1 (en) 2022-01-27 2024-12-04 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN116554042A (zh) * 2022-01-30 2023-08-08 康希诺生物股份公司 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
CN120420422A (zh) * 2022-01-30 2025-08-05 康希诺生物股份公司 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
WO2023143600A1 (zh) * 2022-01-30 2023-08-03 康希诺生物股份公司 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
EP4472673A1 (en) 2022-02-02 2024-12-11 BioNTech SE Agents and methods for targeted delivery of nucleic acids to cells
EP4472672A1 (en) 2022-02-02 2024-12-11 BioNTech SE Agents and methods for targeted delivery to cells
EP4475882A1 (en) 2022-02-09 2024-12-18 ModernaTX, Inc. Mucosal administration methods and formulations
EP4479085A1 (en) 2022-02-18 2024-12-25 ModernaTX, Inc. Mrnas encoding checkpoint cancer vaccines and uses thereof
EP4482819A2 (en) * 2022-02-24 2025-01-01 Vivasor, Inc. Novel ionizable cationic lipids
WO2023165582A1 (zh) * 2022-03-04 2023-09-07 益杰立科(上海)生物科技有限公司 靶向递送系统和方法
KR20240161965A (ko) 2022-03-14 2024-11-13 제너레이션 바이오 컴퍼니 이종 프라임 부스트 백신 조성물 및 사용 방법
WO2023177904A1 (en) 2022-03-18 2023-09-21 Modernatx, Inc. Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
CN116813493A (zh) * 2022-03-21 2023-09-29 苏州科锐迈德生物医药科技有限公司 一种脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN114380724B (zh) * 2022-03-23 2022-05-24 深圳市瑞吉生物科技有限公司 用于递送核酸的阳离子脂质化合物和组合物及用途
KR20240166554A (ko) 2022-03-25 2024-11-26 세일 바이오메디슨스, 인크. 신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
CN114890907B (zh) * 2022-03-31 2023-10-31 荣灿生物医药技术(上海)有限公司 一种阳离子脂质化合物及其制备方法和应用
WO2023193892A1 (en) * 2022-04-05 2023-10-12 BioNTech SE Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
JP2025511756A (ja) 2022-04-08 2025-04-16 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー ワクチン及び関連する方法
WO2023201204A1 (en) 2022-04-11 2023-10-19 Modernatx, Inc. Detection of mrna purity in a mixture
AU2023260227A1 (en) 2022-04-27 2024-11-21 Shanghai Regenelead Therapies Co., Ltd Nucleic acid construct and use thereof
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
EP4522753A2 (en) 2022-05-13 2025-03-19 Flagship Pioneering Innovations VII, LLC Double stranded dna compositions and related methods
WO2023218431A1 (en) 2022-05-13 2023-11-16 BioNTech SE Rna compositions targeting hiv
JP2025515206A (ja) 2022-05-13 2025-05-13 上海瑞宏迪医薬有限公司 Ｕｔｒを含む核酸構築物及びその使用
WO2023218420A1 (en) 2022-05-13 2023-11-16 Janssen Pharmaceuticals, Inc. Mrna compositions for inducing latent hiv-1 reversal
US20250340586A1 (en) 2022-05-17 2025-11-06 Modernatx, Inc. Preparation of highly concentrated mrna
US20250345407A1 (en) 2022-05-25 2025-11-13 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2023230295A1 (en) 2022-05-25 2023-11-30 BioNTech SE Rna compositions for delivery of monkeypox antigens and related methods
WO2023230601A1 (en) 2022-05-27 2023-11-30 Beam Therapeutics Inc. Identification of nanoparticles for preferential tissue or cell targeting
CN119562807A (zh) 2022-05-30 2025-03-04 生物技术公司 用于递送核酸的复合物
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
JP2025520127A (ja) 2022-06-02 2025-07-01 スクライブ・セラピューティクス・インコーポレイテッド 操作されたクラス２タイプｖ ｃｒｉｓｐｒ系
CA3258303A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Compositions of lipid nanoparticles and their uses
CA3257914A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. COMPOSITIONS AND METHODS FOR TARGETING PCSK9
EP4536819A1 (en) 2022-06-07 2025-04-16 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
EP4539876A2 (en) 2022-06-18 2025-04-23 GlaxoSmithKline Biologicals S.A. Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
CN114773217B (zh) * 2022-06-20 2022-10-18 深圳市瑞吉生物科技有限公司 用于递送核酸的阳离子脂质化合物和组合物及用途
US20250179492A1 (en) 2022-06-22 2025-06-05 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
CN114989182B (zh) * 2022-06-23 2023-06-23 尧唐(上海)生物科技有限公司 脂质化合物、包含其的组合物及应用
US20240082425A1 (en) 2022-06-23 2024-03-14 Turn Biotechnologies, Inc. Lipid structures and compositions comprising same
WO2023248128A1 (en) 2022-06-23 2023-12-28 Pfizer Inc. Use of a spray freeze-drying process for the lyophilization of a mrna-encapsulating lipid nanoparticles formulation
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2023250119A1 (en) 2022-06-24 2023-12-28 Modernatx, Inc. Methods of producing rna
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN119855910A (zh) 2022-07-06 2025-04-18 美国微哲默理有限责任公司 用于治疗胰腺癌的组合物和方法
EP4551247A1 (en) 2022-07-07 2025-05-14 The United States of America, as represented by the Secretary, Department of Health and Human Services Immunogens and methods for inducing an immune response
WO2024012270A1 (zh) 2022-07-11 2024-01-18 传信生物医药(苏州)有限公司 用于核酸的器官特异性递送组合物
AU2023306438A1 (en) * 2022-07-15 2025-02-20 Shenzhen Shenxin Biotechnology Co., Ltd. Amino lipid compound, preparation method therefor, composition thereof and application thereof
CN120344660A (zh) 2022-07-18 2025-07-18 雷纳嘉德医疗管理公司 基因编辑组分、系统和使用方法
WO2024019936A1 (en) 2022-07-20 2024-01-25 Beam Therapeutics Inc. Nanomaterials comprising triols
AU2023317702A1 (en) 2022-08-01 2025-01-09 BioNTech SE Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
TW202413424A (zh) 2022-08-01 2024-04-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫調節蛋白及相關方法
CN114989027B (zh) * 2022-08-03 2023-01-31 深圳市瑞吉生物科技有限公司 用于递送核酸的阳离子脂质化合物和组合物及用途
WO2024027910A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
WO2024028445A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
CN117126071A (zh) * 2022-08-12 2023-11-28 上海蓝鹊生物医药有限公司 含氮链状化合物、其制备方法、包含其的组合物和应用
EP4569112A1 (en) 2022-08-12 2025-06-18 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN120435557A (zh) 2022-08-19 2025-08-05 图恩疗法股份有限公司 通过靶向基因阻遏调节乙型肝炎病毒的组合物、系统和方法
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
CN115557875B (zh) * 2022-08-19 2025-01-03 上海耐澄生物科技有限公司 一种脂质化合物及脂质纳米颗粒
WO2024044147A1 (en) 2022-08-23 2024-02-29 Modernatx, Inc. Methods for purification of ionizable lipids
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024049979A2 (en) 2022-08-31 2024-03-07 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2024051825A1 (zh) 2022-09-09 2024-03-14 厦门赛诺邦格生物科技股份有限公司 一种碳核阳离子脂质
EP4587166A1 (en) 2022-09-15 2025-07-23 Pfizer Inc. Coaxial flow device for nanoparticle preparation and manufacturing equipment including such device
WO2024057237A1 (en) 2022-09-16 2024-03-21 Pfizer Inc. Lipid nanoparticles
KR20250073120A (ko) * 2022-09-19 2025-05-27 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 2-히드록시에틸 아미노카프로에이트계 화합물을 제조하는 방법 및 이의 용도
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
AU2023347390A1 (en) 2022-09-23 2025-04-10 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
IL319414A (en) 2022-09-23 2025-05-01 BioNTech SE Compositions for delivering antigens at the liver level and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
AU2023353931A1 (en) 2022-09-26 2025-03-20 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
AU2023357320A1 (en) 2022-10-06 2025-04-17 BioNTech SE Rna compositions targeting claudin-18.2
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
TWI888970B (zh) 2022-10-27 2025-07-01 美商輝瑞大藥廠 Rna分子
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
KR20250099195A (ko) 2022-10-31 2025-07-01 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
CN115417778B (zh) * 2022-11-01 2023-06-20 北京华芢生物技术有限公司 可离子化的阳离子脂c5及由其组成的纳米脂质体颗粒
CN115433099B (zh) * 2022-11-03 2023-06-16 北京华芢生物技术有限公司 可离子化的阳离子脂c6及由其组成的纳米脂质体颗粒
US20250367129A1 (en) 2022-11-04 2025-12-04 Pfizer Inc. Lipid Compounds and Uses Thereof
WO2024094211A1 (zh) * 2022-11-06 2024-05-10 斯微(上海)生物科技股份有限公司 一种脂质组合物
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
AR131008A1 (es) 2022-11-08 2025-02-05 Flagship Pioneering Innovations Vi Llc Composiciones y métodos para producir polirribonucleótidos circulares
AU2023375897A1 (en) 2022-11-08 2025-06-12 Orna Therapeutics, Inc. Circular rna compositions
JP2025537750A (ja) 2022-11-10 2025-11-20 セイル バイオメディシンズ インコーポレイテッド 脂質ナノ粒子または脂質再構成天然メッセンジャーパックを含むｒｎａ組成物
CN120265279A (zh) 2022-11-21 2025-07-04 翻译生物公司 信使rna的干粉配制品的组合物及其使用方法
AU2023383821A1 (en) 2022-11-24 2025-05-29 Themedium Therapeutics Co., Ltd Novel lipids used for nucleic acid delivery and lipid nanoparticle composition
WO2024119051A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
EP4626402A1 (en) 2022-12-01 2025-10-08 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
JP2025541726A (ja) 2022-12-01 2025-12-23 ジェネレーション バイオ カンパニー 細胞標的化のためのステルス脂質ナノ粒子組成物
KR20250129819A (ko) 2022-12-01 2025-08-29 제너레이션 바이오 컴퍼니 핵산, 이온화 가능한 지질, 스테롤, 지질에 고정된 중합체, 및 헬퍼 지질을 포함하는 지질 나노입자 및 이의 용도
WO2024123633A1 (en) 2022-12-08 2024-06-13 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
EP4630561A1 (en) 2022-12-09 2025-10-15 Takeda Pharmaceutical Company Limited Modified immunomodulators
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
EP4633673A1 (en) 2022-12-15 2025-10-22 Sanofi Pasteur Inc. Mrna encoding influenza virus-like particle
EP4637812A1 (en) 2022-12-19 2025-10-29 GlaxoSmithKline Biologicals S.A. Hepatitis b compositions
KR20240096964A (ko) 2022-12-19 2024-06-27 주식회사 녹십자 핵산 전달용 사이클로알칸계 지질 화합물 및 이를 포함하는 지질 나노입자
TW202438514A (zh) 2022-12-20 2024-10-01 法商賽諾菲公司 鼻病毒mrna疫苗
EP4637718A1 (en) * 2022-12-21 2025-10-29 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticles comprising sterol-modified phospholipids
WO2024134551A1 (en) 2022-12-23 2024-06-27 Pfizer Inc. Lipid particle compositions and methods of use thereof
CN121127490A (zh) 2022-12-28 2025-12-12 生物技术欧洲股份公司 靶向hiv的rna组合物
TW202438063A (zh) * 2022-12-28 2024-10-01 日商安斯泰來製藥股份有限公司 ４－胺基哌啶化合物、其脂質奈米粒子，及含有其之醫藥組成物
WO2024141784A2 (en) 2022-12-29 2024-07-04 Popvax Private Limited Broadly protective betacoronavirus vaccines and compositions
KR20250130586A (ko) 2022-12-29 2025-09-02 리누아진 바이오테크놀로지 씨오., 엘티디. Hpv 감염-관련 질병을 예방 또는 치료하기 위한 폴리뉴클레오티드 분자
WO2024141786A2 (en) 2022-12-29 2024-07-04 Popvax Private Limited Multitarget vaccines and therapeutics
CN116178193B (zh) 2023-01-05 2023-07-28 北京悦康科创医药科技股份有限公司 高效低毒且稳定性表达的阳离子脂质化合物及其组合物
CN116375592B (zh) * 2023-01-05 2025-05-16 北京悦康科创医药科技股份有限公司 长效低毒的新型阳离子脂质化合物及其组合物
CN115677518B (zh) * 2023-01-05 2023-04-14 北京悦康科创医药科技股份有限公司 用于递送核酸的可电离阳离子脂质化合物和组合物及用途
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
WO2024151673A2 (en) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
TW202438673A (zh) 2023-01-09 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 疫苗及相關方法
EP4648793A1 (en) 2023-01-11 2025-11-19 ModernaTX, Inc. Personalized cancer vaccines
WO2024154052A1 (en) 2023-01-16 2024-07-25 Pfizer Inc. Immunogenic compositions and methods of inducing an immune response against varicella zoster virus
WO2024153324A1 (en) 2023-01-18 2024-07-25 BioNTech SE Rna formulations for pharmaceutical use
AU2024212425A1 (en) 2023-01-27 2025-08-07 Sail Biomedicines, Inc. A modified lipid composition and uses thereof
EP4658636A1 (en) 2023-01-31 2025-12-10 Pfizer Inc. Lipid compounds and uses thereof
EP4658239A1 (en) 2023-02-03 2025-12-10 GlaxoSmithKline Biologicals S.A. Rna formulation
WO2024167885A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
WO2024165146A1 (en) 2023-02-07 2024-08-15 Biontech Cell & Gene Therapies Gmbh Immune effector cells stably and transiently expressing nucleic acids
CN115784921B (zh) 2023-02-08 2023-05-05 北京悦康科创医药科技股份有限公司 肝外靶向高效低毒的阳离子脂质化合物及其组合物
IL322468A (en) 2023-02-13 2025-09-01 Flagship Pioneering Innovations Vii Llc Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
AU2024220221A1 (en) 2023-02-17 2025-08-07 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified cytosine
EP4665405A1 (en) 2023-02-17 2025-12-24 Flagship Pioneering Innovations VII, LLC Dna compositions comprising modified uracil
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
CN121002196A (zh) 2023-02-28 2025-11-21 百欧恩泰欧洲股份公司 用于多种编码核酸的接头序列效力测定
WO2024180363A1 (en) 2023-02-28 2024-09-06 BioNTech SE Linker sequence potency assays for multiple coding nucleic acids
DE112024001143T5 (de) 2023-03-08 2025-12-18 CureVac SE Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
CN121127584A (zh) 2023-03-09 2025-12-12 生物技术公司 具有杀细菌活性的肽聚糖水解酶
WO2024192422A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
AU2024236558A1 (en) 2023-03-15 2025-10-09 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
KR20250162610A (ko) 2023-03-15 2025-11-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
AU2024234874A1 (en) 2023-03-15 2025-10-09 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024194767A1 (en) 2023-03-17 2024-09-26 BioNTech SE Automated drug production system
CN118666726A (zh) * 2023-03-17 2024-09-20 尧唐(上海)生物科技有限公司 递送治疗剂的脂质化合物及其制备方法与应用
WO2024193827A1 (en) 2023-03-23 2024-09-26 BioNTech SE Stabilized nucleic acid compositions and methods for preparing, storing and using the same
TW202444914A (zh) 2023-03-29 2024-11-16 美商斯奎柏治療公司 抑制子融合蛋白系統
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
TW202444906A (zh) 2023-03-29 2024-11-16 美商斯奎柏治療公司 用於靶向pcsk9之組合物及方法
TW202444921A (zh) 2023-03-29 2024-11-16 美商斯奎柏治療公司 用於靶向lpa之組合物及方法
WO2024206835A1 (en) 2023-03-30 2024-10-03 Modernatx, Inc. Circular mrna and production thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
TW202449142A (zh) 2023-04-07 2024-12-16 日商武田藥品工業股份有限公司 接合複合物
WO2024209418A1 (en) 2023-04-07 2024-10-10 BioNTech SE Heating and cooling jacket for fluid vessels
AU2024255972A1 (en) 2023-04-12 2025-10-23 Flagship Pioneering Innovations Vi, Llc Modified trems, compositions, and related methods thereof
AU2024252590A1 (en) 2023-04-12 2025-10-23 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
WO2024216214A1 (en) 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
WO2024213776A1 (en) 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
WO2024216217A1 (en) 2023-04-14 2024-10-17 BioNTech SE Hiv vaccine
WO2024216212A1 (en) 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
KR20250169625A (ko) 2023-04-17 2025-12-03 사노피 파스퇴르 인크 재구성 가능한 건조 분말 제형 및 이의 사용 방법
WO2024220625A1 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024220752A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Rna therapeutic compositions
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
WO2024223728A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
CN117384055B (zh) * 2023-04-27 2024-11-19 仁景(苏州)生物科技有限公司 用于递送治疗剂的可电离脂质及其用途
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024229309A2 (en) 2023-05-03 2024-11-07 Manifold Biotechnologies, Inc. Methodsand compositions for high-throughput protein delivery, screening, and detection
WO2024228044A1 (en) 2023-05-03 2024-11-07 BioNTech SE Optimized csp variants and related methods
CN121038807A (zh) 2023-05-03 2025-11-28 生物技术欧洲股份公司 优化的csp变体及相关方法
WO2024233308A2 (en) 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2024238700A1 (en) 2023-05-15 2024-11-21 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2024236504A1 (en) 2023-05-15 2024-11-21 Takeda Pharmaceutical Company Limited Sequences and methods for delivery of dna and rna
WO2024236361A1 (en) 2023-05-15 2024-11-21 Takeda Pharmaceutical Company Limited Compositions and methods for delivery of nucleic acids to cells
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2024243438A2 (en) 2023-05-23 2024-11-28 Omega Therapeutics, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2024256962A1 (en) 2023-06-14 2024-12-19 Pfizer Inc. Method for stabilizing rna
CN119143620A (zh) * 2023-06-16 2024-12-17 北京剂泰医药科技有限公司 一种快速代谢的脂质化合物
WO2024260570A1 (en) 2023-06-23 2024-12-26 CureVac SE Nucleic acid encoded antibodies
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2025003760A1 (en) 2023-06-28 2025-01-02 Sanofi Sterol analogs in lipid nanoparticle formulations
WO2025003406A1 (en) 2023-06-29 2025-01-02 BioNTech SE Modular multiplatform system for mrna drug production
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025002359A1 (zh) * 2023-06-30 2025-01-02 深圳深信生物科技有限公司 水痘带状疱疹病毒(vzv)疫苗
WO2025006385A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Novel malaria vaccine comprising ama1 and ron2 antigens
WO2025011529A2 (en) 2023-07-07 2025-01-16 Shanghai Circode Biomed Co., Ltd. Circular rna vaccines for seasonal flu and methods of uses
TW202515531A (zh) 2023-07-07 2025-04-16 美商輝瑞股份有限公司 兩親性ｔｌｒ７／８佐劑及其用途
WO2025017476A1 (en) 2023-07-19 2025-01-23 Pfizer Inc. Lipid nanoparticles comprising polymer-conjugated lipids and uses thereof
WO2025021277A1 (en) 2023-07-21 2025-01-30 BioNTech SE Agents and methods for targeted delivery of cytokines to immune cells
WO2025024324A1 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025024337A1 (en) 2023-07-24 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
TW202516001A (zh) 2023-07-25 2025-04-16 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 Ｃａｓ內切酶及相關方法
WO2025026545A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thioplipids and uses thereof
WO2025027116A1 (en) 2023-08-01 2025-02-06 Institut Curie Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
TW202519509A (zh) 2023-08-01 2025-05-16 德商拜恩技術股份公司 可離子化硫脂質及其用途
WO2025026553A1 (en) 2023-08-02 2025-02-06 BioNTech SE Agents and methods for targeted delivery to cells
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
WO2025030097A2 (en) 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025027576A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
WO2025030154A1 (en) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
WO2025036992A1 (en) 2023-08-16 2025-02-20 CureVac SE Rna conjugates
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025045142A1 (en) 2023-08-29 2025-03-06 Shanghai Circode Biomed Co., Ltd. Circular rna encoding vegf polypeptides, formulations, and methods of uses
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025052180A2 (en) 2023-09-07 2025-03-13 Axelyf ehf. Lipids and lipid nanoparticles
WO2025051994A1 (en) 2023-09-07 2025-03-13 Coave Therapeutics Ionizable lipid nanoparticles
WO2025054556A1 (en) 2023-09-07 2025-03-13 BioNTech SE Rna compositions for delivery of mpox antigens and related methods
WO2025057088A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
CN119591513A (zh) * 2023-09-11 2025-03-11 苏州星核迪赛生物技术有限公司 局部递送药物的材料及其应用
WO2025057115A2 (en) 2023-09-15 2025-03-20 Pfizer Inc. Methods and compositions for continuous production of nucleic acids
TW202525266A (zh) 2023-09-18 2025-07-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 可電離類脂質組成物及其治療用途
WO2025061863A1 (en) 2023-09-20 2025-03-27 BioNTech SE Method
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025082397A1 (zh) * 2023-10-19 2025-04-24 仁景(苏州)生物科技有限公司 用于递送的脂质化合物及脂质纳米颗粒
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
WO2025093665A1 (en) 2023-10-31 2025-05-08 BioNTech SE Particles, compositions and methods
CN118147134B (zh) 2023-11-06 2025-02-25 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用
WO2025101501A1 (en) 2023-11-07 2025-05-15 Orna Therapeutics, Inc. Circular rna compositions
CN117550985B (zh) * 2023-11-08 2025-02-18 深圳厚存纳米药业有限公司 一种脂质化合物及其用途
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
TW202535835A (zh) 2023-11-14 2025-09-16 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 可電離類脂質組成物及其治療用途
KR20250071877A (ko) 2023-11-15 2025-05-22 바이오엔테크 에스이 Sars-cov-2 면역원성 조성물
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
US20250161227A1 (en) 2023-11-17 2025-05-22 Acuitas Therapeutics, Inc. Pegylated lipids
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025106930A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
EP4559898A1 (en) 2023-11-24 2025-05-28 AldexChem Kft. Novel ionizable cationic lipids containing thioether linkage
WO2025114520A1 (en) 2023-12-01 2025-06-05 Coave Therapeutics Ionizable lipid nanoparticles
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
US12364773B2 (en) 2023-12-01 2025-07-22 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
US20250188016A1 (en) 2023-12-12 2025-06-12 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025132122A1 (en) 2023-12-13 2025-06-26 Berlin Institute Of Health Methods of delivering therapeutics using lipid nanoparticles
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025126019A1 (en) 2023-12-13 2025-06-19 Pfizer Inc. Rna molecules
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025129128A1 (en) 2023-12-15 2025-06-19 Vivasor, Inc. Compositions and methods for non-viral delivery of therapeutic compounds
WO2025126113A1 (en) 2023-12-15 2025-06-19 Pfizer Inc. Lipid compounds and uses thereof
WO2025126118A1 (en) 2023-12-15 2025-06-19 Pfizer Inc. Lipid compounds and uses thereof
WO2025133115A1 (en) 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
WO2025134066A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025134062A2 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025133105A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Compositions and methods
WO2025137646A1 (en) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Gene editing methods and compositions for treating cystic fibrosis
WO2025134046A1 (en) 2023-12-22 2025-06-26 Pfizer Inc. Methods and vaccine compositions for lyme disease
WO2025144938A1 (en) 2023-12-26 2025-07-03 Emmune, Inc. Systems for nucleic acid transfer
WO2025141521A1 (en) 2023-12-29 2025-07-03 Sanofi Lipids having dendritic moieties
CN117820149B (zh) * 2023-12-29 2025-01-07 北京剂泰医药科技有限公司 可电离脂质化合物
WO2025149492A1 (en) 2024-01-08 2025-07-17 BioNTech SE Rna encoding an immune inhibitory il-1 family member
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
US20250375499A1 (en) 2024-01-26 2025-12-11 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025166325A1 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025174858A1 (en) 2024-02-15 2025-08-21 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025184508A1 (en) 2024-03-01 2025-09-04 Acuitas Therapeutics, Inc. Materials and methods for encapsulating therapeutics in lipid nanoparticles
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
WO2025196065A1 (en) 2024-03-20 2025-09-25 Sanofi Novel homocysteine based lipids and their use for delivery of nucleic acids
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025202834A1 (en) 2024-03-26 2025-10-02 Pfizer Inc. Polynucleotide compositions and uses thereof
CN118255678B (zh) * 2024-03-28 2024-12-24 荣灿生物医药技术(上海)有限公司 一种可电离脂质化合物及其应用
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
WO2025210520A1 (en) 2024-04-04 2025-10-09 Genevant Sciences Gmbh Lipid nanoparticles for inducing an immunological response
WO2025210521A1 (en) 2024-04-04 2025-10-09 Genevant Sciences Gmbh Lipid nanoparticles for stimulating t cells
WO2025213131A1 (en) 2024-04-05 2025-10-09 BioNTech SE Rna compositions for delivery of orthopox antigens and related methods
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2025217131A1 (en) * 2024-04-08 2025-10-16 Popvax Private Limited Novel lipids for delivery of nucleic acid therapeutics
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2025217264A1 (en) 2024-04-10 2025-10-16 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
CN118319880B (zh) * 2024-04-15 2025-02-07 荣灿生物医药技术(上海)有限公司 靶向肺部高效递送核酸的脂质纳米颗粒、吸入式制剂及应用
WO2025224684A1 (en) 2024-04-24 2025-10-30 BioNTech SE Compositions and methods for producing engineered immune cells
WO2025228975A1 (en) 2024-04-29 2025-11-06 BioNTech SE Particles, compositions and methods
WO2025231114A1 (en) 2024-05-01 2025-11-06 Acuitas Therapeutics, Inc. Method of using lipid nanoparticles for intramuscular delivery
WO2025229572A1 (en) 2024-05-01 2025-11-06 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
WO2025240680A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025240833A1 (en) 2024-05-17 2025-11-20 Acuitas Therapeutics, Inc. Galnac lipid compounds for use in lipid nanoparticles
WO2025240940A1 (en) 2024-05-17 2025-11-20 Scribe Therapeutics Inc. Compositions and methods for the targeting of apolipoprotein c3
WO2025238563A1 (en) 2024-05-17 2025-11-20 Pfizer Inc. Coaxial mixing device for nanoparticle preparation and manufacturing equipment including such mixing device
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2025242815A1 (en) 2024-05-23 2025-11-27 CureVac SE Immunotherapy of squamous cell carcinoma
CN118240844B (zh) 2024-05-27 2024-12-13 北京悦康科创医药科技股份有限公司 带状疱疹mRNA疫苗及其制备方法和应用
WO2025250751A1 (en) 2024-05-31 2025-12-04 Orna Therapeutics, Inc. Circular rna compositions and methods
CN119930462B (zh) * 2025-04-08 2025-06-27 北京悦康科创医药科技股份有限公司 基于RLRs受体激动剂的疫苗佐剂脂质化合物、包含其的组合物及用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001338416A (ja) 2000-05-25 2001-12-07 Sony Corp ディスク状磁気記録媒体
US20020062044A1 (en) 1998-11-09 2002-05-23 Council Of Scientific & Industrial Research Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules
WO2011136368A1 (ja) 2010-04-28 2011-11-03 協和発酵キリン株式会社 カチオン性脂質
JP2013095755A (ja) 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
JP2018532721A (ja) 2015-09-17 2018-11-08 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 治療剤の細胞内送達のための化合物および組成物
JP2019519511A (ja) 2016-05-18 2019-07-11 モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ． Ｉｉ型シトルリン血症の治療のためのシトリンをコードするポリヌクレオチド

Family Cites Families (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE707279C (de) * 1938-05-03 1941-06-18 I G Farbenindustrie Akt Ges Hochmolekulare halogenhaltige Filmbildner
US2856420A (en) 1955-12-15 1958-10-14 Minnesota Mining & Mfg Perfluoro- and perfluorochlorocarboxylic acid esters of amino alcohols
FR1386626A (fr) * 1963-04-02 1965-01-22 Rohm & Haas Compositions résineuses de nitrilopropionates et de polyvinyle
US3340299A (en) 1964-03-27 1967-09-05 Air Reduction Tetrasubstituted ethylene diamines
GB1277947A (en) 1968-08-22 1972-06-14 Armour Ind Chem Co Compositions and method for controlling insect pests
US4491583A (en) 1970-08-07 1985-01-01 Pfizer Inc. Interferon induction in animals by amines
US3729564A (en) 1970-12-16 1973-04-24 Pfizer N-secondary alkyl alkanediamines and derivatives thereof as anti-inflammatory agents
JPS5122416B2 (cg-RX-API-DMAC7.html) 1972-11-11 1976-07-09
DE2633615C3 (de) 1976-07-27 1981-08-13 Bayer Ag, 5090 Leverkusen Verfahren zum Färben von synthetischen Polyamid-Fasermaterialien
DE3010599A1 (de) 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
JPS56150002A (en) 1980-04-23 1981-11-20 Nisshin Flour Milling Co Ltd Nonaprenylamine derivative
US4883751A (en) 1986-05-28 1989-11-28 New York University Specific immunoassay for heparin
US6036957A (en) 1990-03-30 2000-03-14 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
JP2588339B2 (ja) 1992-06-02 1997-03-05 花王株式会社 新規ジアミノジエステル及びその製造法
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
AU723163B2 (en) 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
JPH11510489A (ja) 1995-07-21 1999-09-14 ジンタ・インコーポレイテッド 新規アミド基本カチオン性脂質
DE19605175A1 (de) 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipidverbindungen und deren Verwendung
JPH103643A (ja) 1996-06-12 1998-01-06 Fuji Photo Film Co Ltd ディスク状磁気記録媒体
EP0948587B1 (en) 1996-10-11 2003-05-07 Infineum Holdings BV Fuel compositions
CA2217550A1 (en) 1996-10-22 1998-04-22 F. Hoffmann-La Roche Ag Cationic lipids for gene therapy
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
US5756785A (en) 1997-03-21 1998-05-26 Lambent Technologies, Inc. Guerbet betaines
FR2763943B1 (fr) 1997-05-28 1999-07-09 Rhone Poulenc Rorer Sa Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
EP1041976B1 (en) 1997-12-23 2006-04-05 Inex Pharmaceuticals Corp. Polyamide oligomers
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
US6986902B1 (en) 1998-04-28 2006-01-17 Inex Pharmaceuticals Corporation Polyanionic polymers which enhance fusogenicity
US6013813A (en) 1998-06-17 2000-01-11 Hansotech Inc Guerbet based sorbitan esters
WO2000030444A1 (en) 1998-11-25 2000-06-02 Vanderbilt University Cationic liposomes for gene transfer
US5919743A (en) 1998-12-28 1999-07-06 Petroferm Inc. Guerbet branched quaternary compounds in personal care applications
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
US6211140B1 (en) 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
DE69943068D1 (de) 1999-09-09 2011-02-03 Curevac Gmbh Transfer von mRNA unter Verwendung von polykationischen Verbindungen
GB9930533D0 (en) 1999-12-23 2000-02-16 Mitsubishi Tokyo Pharm Inc Nucleic acid delivery
US20040142474A1 (en) 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
JP4111856B2 (ja) * 2002-04-12 2008-07-02 昭和電工株式会社 安定化されたアスコルビン酸誘導体
EP2338478B1 (en) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Method for producing liposomes
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US6620794B1 (en) 2002-07-08 2003-09-16 Colonial Chemical Inc. Guerbet functionalized phospholipids
JP4951338B2 (ja) 2003-07-16 2012-06-13 プロチバ バイオセラピューティクス インコーポレイティッド 脂質に封入された干渉ｒｎａ
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
JP4842821B2 (ja) 2003-09-15 2011-12-21 プロチバ バイオセラピューティクス インコーポレイティッド ポリエチレングリコール修飾脂質化合物およびその使用
AU2005251691A1 (en) 2004-05-17 2005-12-22 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
EP1937213B1 (en) 2005-07-27 2017-10-25 Protiva Biotherapeutics Inc. Systems and methods for manufacturing liposomes
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
JP4681425B2 (ja) 2005-11-15 2011-05-11 花王株式会社 毛髪弾性改善剤
GB2433928B (en) 2006-01-07 2009-10-14 Shane Richard Wootton Apparatus for producing material by a chemical reaction
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
CN105030654A (zh) 2006-10-03 2015-11-11 阿尔尼拉姆医药品有限公司 含脂质的制品
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
AU2008219165A1 (en) 2007-02-16 2008-08-28 Merck Sharp & Dohme Corp. Compositions and methods for potentiated activity of biologicaly active molecules
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
CA2891005A1 (en) 2007-09-28 2008-10-09 Bind Therapeutics, Inc. Cancer cell targeting using nanoparticles
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
CA2910760C (en) 2007-12-04 2019-07-09 Muthiah Manoharan Targeting lipids
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
AU2008347250A1 (en) 2008-01-02 2009-07-16 Tekmira Pharmaceuticals Corporation Screening method for selected amino lipid-containing compositions
US20110045473A1 (en) 2008-01-02 2011-02-24 De Fougerolles Antonin Liver screening method
HRP20150528T2 (hr) 2008-01-31 2016-03-25 Curevac Gmbh NUKLEINSKE KISELINE KOJE SADRŽE FORMULU (NuGiXmGnNv)a TE NJIHOVI DERIVATI KAO IMUNOSTIMULACIJSKA SREDSTVA/POMOĆNA SREDSTVA
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
WO2009126933A2 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
JP5475753B2 (ja) 2008-04-15 2014-04-16 プロチバ バイオセラピューティクス インコーポレイティッド 核酸送達用の脂質製剤
US20090285881A1 (en) 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
US20090263407A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic Lipids and Uses Thereof
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
EP2285350B1 (en) 2008-06-16 2017-11-15 Pfizer Inc Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles
EP2309991B1 (en) 2008-06-16 2019-03-06 Pfizer Inc Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
EP2309990B2 (en) 2008-06-16 2017-03-15 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
WO2010021865A1 (en) 2008-08-18 2010-02-25 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP3225621A1 (en) 2008-10-09 2017-10-04 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
US20120009222A1 (en) 2008-10-27 2012-01-12 Massachusetts Institute Of Technology Modulation of the immune response
MX338780B (es) 2008-11-10 2016-05-02 Alnylam Pharmaceuticals Inc Lipidos y composiciones novedosas para el suministro de terapeuticos.
US8722082B2 (en) 2008-11-10 2014-05-13 Tekmira Pharmaceuticals Corporation Lipids and compositions for the delivery of therapeutics
CA2742838A1 (en) 2008-11-17 2010-05-20 Enzon Pharmaceuticals, Inc. Releasable polymeric lipids for nucleic acids delivery systems
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
EP3097908A1 (en) 2009-05-05 2016-11-30 Arbutus Biopharma Corporation Lipid compositions
CA2760706C (en) 2009-05-05 2019-08-06 Alnylam Pharmaceuticals, Inc. Methods of delivering oligonucleotides to immune cells
PL2440183T3 (pl) 2009-06-10 2019-01-31 Arbutus Biopharma Corporation Ulepszona formulacja lipidowa
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
EP3072881A1 (en) 2009-08-20 2016-09-28 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
US20120264810A1 (en) * 2009-09-22 2012-10-18 The University Of British Columbia Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
EP2485770A4 (en) 2009-10-08 2013-04-10 Merck Sharp & Dohme Novel cationic lipids with short lipid chains for oligonucleotide delivery
EP2496700B1 (en) 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
WO2011066651A1 (en) 2009-12-01 2011-06-09 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
EP3296398A1 (en) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2011084513A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
JP5898627B2 (ja) 2009-12-15 2016-04-06 バインド セラピューティックス インコーポレイテッド エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
EP3494963A1 (en) 2009-12-18 2019-06-12 The University of British Columbia Methods and compositions for delivery of nucleic acids
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
EP2526113B1 (en) 2010-01-22 2016-08-10 Sirna Therapeutics, Inc. Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
EP2558074B1 (en) 2010-04-08 2018-06-06 The Trustees of Princeton University Preparation of lipid nanoparticles
EP2567952A4 (en) 2010-04-28 2015-11-25 Kyowa Hakko Kirin Co Ltd CATIONIC LIPID
WO2011143230A1 (en) * 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
WO2011141703A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
EP2569276B1 (en) 2010-05-12 2021-02-24 Arbutus Biopharma Corporation Novel cationic lipids and methods of use thereof
JP2013531634A (ja) 2010-05-24 2013-08-08 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
EP4481047A3 (en) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US8748667B2 (en) 2010-06-04 2014-06-10 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
CA2804396C (en) 2010-07-06 2021-06-29 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
AU2011276236B2 (en) 2010-07-06 2016-03-10 Glaxosmithkline Biologicals S.A. Cationic oil-in-water emulsions
US8438734B2 (en) 2010-07-23 2013-05-14 General Electric Company Rail vehicle assembly system and method
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
US20130189351A1 (en) 2010-08-31 2013-07-25 Novartis Ag Lipids suitable for liposomal delivery of protein coding rna
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
SI3981427T1 (sl) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
ES2888231T3 (es) 2010-09-20 2022-01-03 Sirna Therapeutics Inc Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
EP3485913A1 (en) 2010-10-21 2019-05-22 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
US20150056300A1 (en) 2010-10-22 2015-02-26 Bind Therapeutics, Inc. Therapeutic nanoparticles with high molecular weight copolymers
EP2635265B1 (en) 2010-11-05 2018-04-04 Sirna Therapeutics, Inc. Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
WO2012068176A1 (en) 2010-11-15 2012-05-24 Life Technologies Corporation Amine-containing transfection reagents and methods for making and using same
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2013014073A1 (en) 2011-07-22 2013-01-31 Universite De Strasbourg Phospholipid-detergent conjugates and uses thereof
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US9126966B2 (en) * 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
IL293650B2 (en) 2011-09-21 2024-10-01 Sangamo Therapeutics Inc Methods and compositions for regulation of transgene expression
WO2013049328A1 (en) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
DK2768958T3 (da) 2011-10-18 2019-09-16 Dicerna Pharmaceuticals Inc Kationiske aminlipider og anvendelser deraf
CA2856737C (en) 2011-12-07 2023-09-26 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
EP2788006A1 (en) 2011-12-07 2014-10-15 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
AU2013222179B2 (en) 2012-02-24 2017-08-24 Arbutus Biopharma Corporat ion Trialkyl cationic lipids and methods of use thereof
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
DK2830594T3 (en) 2012-03-27 2018-08-13 Sirna Therapeutics Inc DIETHER-BASED BIOLOGICALLY DEGRADABLE CATIONIC LIPIDS FOR siRNA RELEASE
RU2750261C2 (ru) 2012-03-27 2021-06-25 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков и пептидов
RU2660565C2 (ru) 2012-03-27 2018-07-06 Кьюрвак Аг Молекулы искусственной нуклеиновой кислоты, содержащие 5'utr гена top
EP2831239B1 (en) 2012-03-27 2017-11-22 CureVac AG Artificial nucleic acid molecules
US20150306249A1 (en) 2012-05-25 2015-10-29 Curevac Gmbh Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
US9415109B2 (en) 2012-07-06 2016-08-16 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9687448B2 (en) 2012-12-07 2017-06-27 Alnylam Pharmaceuticals, Inc. Nucleic acid lipid particle formulations
SG10201710472PA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
WO2014160284A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of stroke
CA2906110C (en) 2013-03-14 2021-07-27 Dicerna Pharmaceuticals, Inc. Process for formulating an anionic agent
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
CA2915728A1 (en) 2013-08-21 2015-02-26 Thomas Kramps Respiratory syncytial virus (rsv) vaccine
CN105473157A (zh) 2013-08-21 2016-04-06 库瑞瓦格股份公司 组合疫苗
MX2016002153A (es) 2013-08-21 2017-03-01 Curevac Ag Composicion y vacuna para tratar cancer de prostata.
RU2712743C2 (ru) 2013-08-21 2020-01-30 Куревак Аг Вакцина против бешенства
WO2015024667A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Method for increasing expression of rna-encoded proteins
CA2925021C (en) 2013-11-01 2025-05-06 Curevac Ag MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES
AU2014348212C1 (en) 2013-11-18 2018-11-29 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
US20170042870A1 (en) 2014-02-17 2017-02-16 The Brigham And Women's Hospital, Inc. Targeted nanoparticle compositions and methods of their use to treat obesity
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
ES3009962T3 (en) 2014-04-23 2025-03-31 Modernatx Inc Nucleic acid vaccines
CN106537012B (zh) 2014-05-22 2019-02-12 福斯有限责任公司 用于阀致动器的引导元件和设置有所述引导元件的致动器
CN106795096B (zh) 2014-06-25 2020-05-29 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
JP6339884B2 (ja) 2014-07-17 2018-06-06 富士フイルム株式会社 イミダゾール化合物およびそれを含有するリポソーム
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
EP3230458B1 (en) 2014-12-12 2020-02-19 CureVac AG Artificial nucleic acid molecules for improved protein expression
EP3233113A1 (en) 2014-12-16 2017-10-25 CureVac AG Ebolavirus and marburgvirus vaccines
CA2966092A1 (en) 2014-12-30 2016-07-07 Curevac Ag Artificial nucleic acid molecules
CN104876831B (zh) 2015-04-03 2017-05-17 苏州圣诺生物医药技术有限公司 脂质修饰精胺衍生物及利用该衍生物制备的脂质体
EP3283059B1 (en) 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Method for producing rna compositions
EP3289083A4 (en) * 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
ES2875589T3 (es) 2015-05-15 2021-11-10 Curevac Ag Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm
US20180296663A1 (en) 2015-06-17 2018-10-18 Curevac Ag Vaccine composition
HRP20240865T1 (hr) 2015-06-29 2024-10-11 Acuitas Therapeutics Inc. Lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
EP3331555A1 (en) 2015-08-05 2018-06-13 CureVac AG Epidermal mrna vaccine
DK3332019T3 (da) 2015-08-07 2020-02-17 Curevac Ag Fremgangsmåde til in vivo-produktionen af rna i en værtscelle
KR102645398B1 (ko) 2015-08-28 2024-03-07 큐어백 에스이 신규 인공 핵산 분자
WO2017048770A1 (en) 2015-09-15 2017-03-23 Regulus Therapeutics, Inc. Systems, compositions, and methods for formulating nucleic acid compositions
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
AU2016343803B2 (en) 2015-10-28 2021-04-29 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017081110A1 (en) 2015-11-09 2017-05-18 Curevac Ag Rotavirus vaccines
US20180312545A1 (en) 2015-11-09 2018-11-01 Curevac Ag Optimized nucleic acid molecules
SMT202200252T1 (it) 2015-12-22 2022-07-21 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti
US20190022247A1 (en) 2015-12-30 2019-01-24 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
US20170266292A1 (en) 2016-03-21 2017-09-21 The Research Foundation For The State University Of New York Lipidic compound-telodendrimer hybrid nanoparticles and methods of making and uses thereof
CN109475646A (zh) 2016-03-30 2019-03-15 因特利亚治疗公司 用于crispr/cas成分的脂质纳米颗粒制剂
EP3445392A1 (en) 2016-04-22 2019-02-27 CureVac AG Rna encoding a tumor antigen
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
ES2871537T3 (es) 2016-05-09 2021-10-29 Astrazeneca Ab Nanopartículas lipídicas que comprenden agentes antiinflamatorios lipófilos y métodos de uso de las mismas
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
MX2019004913A (es) 2016-10-26 2019-09-16 Curevac Ag Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
EP3532103B1 (en) 2016-10-26 2025-12-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US20190274968A1 (en) 2016-10-27 2019-09-12 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
WO2018107026A1 (en) 2016-12-09 2018-06-14 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2018191719A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
EP4410317A3 (en) 2017-04-28 2024-10-30 Acuitas Therapeutics Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2019036008A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
EP3668834B1 (en) 2017-08-17 2024-10-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
BR112020007884A2 (pt) 2017-11-20 2020-11-03 Janssen Pharmaceuticals, Inc. método de proporcionar uma administração segura de vetores adenovirais que codificam um antígeno de vírus zika
IL322436A (en) 2018-09-21 2025-09-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
EP3867225A1 (en) 2018-10-18 2021-08-25 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
FI4182297T3 (fi) 2020-07-16 2025-12-05 Acuitas Therapeutics Inc Kationisia lipidejä käytettäväksi lipidinanohiukkasissa

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062044A1 (en) 1998-11-09 2002-05-23 Council Of Scientific & Industrial Research Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules
JP2001338416A (ja) 2000-05-25 2001-12-07 Sony Corp ディスク状磁気記録媒体
WO2011136368A1 (ja) 2010-04-28 2011-11-03 協和発酵キリン株式会社 カチオン性脂質
JP2013095755A (ja) 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
JP2018532721A (ja) 2015-09-17 2018-11-08 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 治療剤の細胞内送達のための化合物および組成物
JP2019519511A (ja) 2016-05-18 2019-07-11 モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ． Ｉｉ型シトルリン血症の治療のためのシトリンをコードするポリヌクレオチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of the American Chemical Sciety，2007年，129(37)，11408-11420

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024081666A (ja) * 2015-10-28 2024-06-18 アクイタス セラピューティクス インコーポレイテッド 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤
JP7789819B2 (ja) 2015-10-28 2025-12-22 アクイタス セラピューティクス インコーポレイテッド 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤

Also Published As

Publication number Publication date
AU2023274244A1 (en) 2023-12-21
CA3003055A1 (en) 2017-05-04
PL3368507T3 (pl) 2023-03-27
US11040112B2 (en) 2021-06-22
WO2017075531A1 (en) 2017-05-04
HRP20230209T1 (hr) 2023-04-14
EP3368507B1 (en) 2022-12-07
US20240075163A1 (en) 2024-03-07
JP7789819B2 (ja) 2025-12-22
JP2022081512A (ja) 2022-05-31
US20220072155A1 (en) 2022-03-10
AU2016343803B2 (en) 2021-04-29
US10166298B2 (en) 2019-01-01
IL258501A (en) 2018-05-31
CN108368028A (zh) 2018-08-03
AU2016343803A1 (en) 2018-04-26
US20170119904A1 (en) 2017-05-04
EP4212510A1 (en) 2023-07-19
JP2024081666A (ja) 2024-06-18
US11712481B2 (en) 2023-08-01
LT3368507T (lt) 2023-03-10
SMT202300052T1 (it) 2023-05-12
JP7453269B2 (ja) 2024-03-19
CA3201644A1 (en) 2017-05-04
DK3368507T3 (da) 2023-02-27
RS63986B1 (sr) 2023-03-31
US11648324B2 (en) 2023-05-16
AU2021206881B2 (en) 2023-09-07
EP3368507A1 (en) 2018-09-05
CN108368028B (zh) 2021-09-03
ES2938557T3 (es) 2023-04-12
JP2018533573A (ja) 2018-11-15
IL286515B1 (en) 2023-10-01
US20200121809A1 (en) 2020-04-23
FI3368507T3 (fi) 2023-03-21
CN113636947A (zh) 2021-11-12
HUE061564T2 (hu) 2023-07-28
CA3003055C (en) 2023-08-01
AU2016343803A8 (en) 2018-06-07
IL286515B2 (en) 2024-02-01
AU2021206881A1 (en) 2021-08-19
SI3368507T1 (sl) 2023-04-28
US20190314524A1 (en) 2019-10-17
IL307179A (en) 2023-11-01
IL258501B (en) 2021-10-31
PT3368507T (pt) 2023-02-07
IL286515A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
JP7453269B2 (ja) 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤
JP6957573B2 (ja) 核酸の送達のための新規脂質および脂質ナノ粒子製剤
JP7355731B2 (ja) 脂質ナノ粒子製剤における使用のための脂質
JP2022505234A (ja) 活性剤の脂質ナノ粒子送達のための脂質
JP2021169462A (ja) 核酸の送達のための脂質および脂質ナノ粒子製剤
WO2018191657A1 (en) Lipids for delivery of active agents
HK40064048A (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HK40096542A (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HK40090394A (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HK1260362A1 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HK1260362B (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191025

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220222

R150 Certificate of patent or registration of utility model

Ref document number: 7030690

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250